)
Edge6 Mar 2026
Upvoted: The Story of Reddit
How Reddit built a unique platform around communities and conversation, turning human insight and intent into a distinctive business model.
Candel Therapeutics
Candel Therapeutics (CADL) investor relations material
Candel Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Advanced clinical pipeline with pivotal phase 3 trials planned for aglatimagene in NSCLC and BLA submission for prostate cancer in 2026.
IND clearance for linoserpaturev in rHGG and encouraging survival data from phase 1b trial.
Strengthened financial position through $130M term loan, $100M equity offering, and $100M royalty funding agreement.
Financial highlights
Research and development expenses rose to $11.0M in Q4 2025 (from $4.8M in Q4 2024) and $30.5M for FY 2025 (from $19.3M in FY 2024).
General and administrative expenses increased to $4.7M in Q4 2025 (from $3.3M in Q4 2024) and $17.8M for FY 2025 (from $14.1M in FY 2024).
Net loss for Q4 2025 was $29.5M (vs. $14.1M in Q4 2024); FY 2025 net loss was $38.2M (vs. $55.2M in FY 2024).
Cash and cash equivalents were $119.7M as of Dec 31, 2025, up from $102.7M at year-end 2024.
Outlook and guidance
Cash runway expected to fund operations into Q1 2028, including commercial launch preparations for aglatimagene.
Key data readouts for aglatimagene in NSCLC and prostate cancer, and linoserpaturev in rHGG, expected throughout 2026.
BLA submission for aglatimagene in prostate cancer planned for Q4 2026.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Candel Therapeutics
- Pivotal phase III success in prostate cancer and promising glioma data drive 2024 milestones.CADL
TD Cowen 46th Annual Health Care Conference3 Mar 2026 - Late-stage viral immunotherapies show strong survival gains in multiple solid tumors.CADLH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Viral immunotherapies show strong survival gains in late-stage cancer trials, with key data imminent.CADLJefferies London Healthcare Conference 202413 Jan 2026
- Significant disease-free survival and response gains with favorable safety profile.CADLStudy Result11 Jan 2026
- Up to $300M in securities registered, including $50M at-the-market stock via Jefferies.CADLRegistration Filing16 Dec 2025
- CAN-2409 shows robust efficacy in prostate cancer, with BLA filing targeted for Q4 2026.CADLCantor Global Healthcare Conference 202516 Dec 2025
- CAN-2409 and CAN-3110 show strong clinical efficacy, safety, and commercial potential in major cancers.CADLCorporate Presentation12 Dec 2025
- Phase III success and regulatory progress drive late-stage immunotherapy pipeline growth.CADLR&D Day 20256 Dec 2025
- CAN-2409 and CAN-3110 show strong efficacy, safety, and commercial promise across major cancers.CADLCorporate Presentation5 Dec 2025
Next Candel Therapeutics earnings date
Q1 202614 May, 2026
Candel Therapeutics
Next Candel Therapeutics earnings date
Q1 202614 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage